Reid Health using new technology to treat heart failure
Photo illustrates the size of the device
A new technology now being used at Reid Health is designed to help manage and reduce hospital admissions for patients with heart failure.
The CardioMEMS HF System is the first and only FDA-approved heart failure monitoring device that has been proven to significantly reduce hospital admissions when used by physicians to manage heart failure. The system features a sensor that is implanted in the pulmonary artery during a non-surgical procedure to directly measure artery pressure. Increased pressures appear before weight and blood pressure changes, which are often used as indirect measures that indicate worsening heart failure. The new system allows patients to transmit daily sensor readings from their homes to their health care providers, allowing for personalized and proactive management of the condition and reduce complications and readmissions for care.
"We are excited to have this great tool to help treat and improve outcomes for our heart failure patients," said Rubinder Dab, M.D., with Richmond Cardiology Associates. He recently performed the first procedure at Reid Health using the new system.
Heart failure occurs when the heart is unable to pump enough blood to meet the body's demands. According to the American Heart Association, nearly 6 million Americans have heart failure and 900,000 new patients are diagnosed each year. Patients with heart failure are frequently hospitalized, have a reduced quality of life and face a higher risk of death. The Centers for Disease Control and Prevention says that half of heart failure patients die within five years of diagnosis.
"Reid Health is known for our arsenal of the latest technologies designed to maximize our physicians' ability to provide the highest standard of care," said Kelly Beall, Vice President/Executive Director, Reid Health Physician Associates. "Our Governing Board knows and always supports the benefits of technology in the hands of highly trained, compassionate physicians and caregivers."
CardioMEMS sensor is designed to last the lifetime of the patient and doesn't
require batteries. Once implanted, the wireless sensor sends pressure readings
to an external patient electronic system. There is no pain or sensation for the
patient during the readings. The CardioMEMS HF System allows the patients to
transmit critical information about their heart failure status to a clinician
on a regular basis, without the need for additional clinic or hospital visits.
This provides clinicians with the ability to detect worsening heart failure
sooner and adjust treatment to reduce the likelihood that the patient will need
to be hospitalized.
from a clinical trial showed that the CardioMEMS technology
reduces heart failure hospital admissions by up to 37 percent. The CHAMPION
trial studied the effectiveness of the CardioMEMS HF System in New York Heart
Association (NYHA) Functional Classification System Class III heart failure
patients who had been hospitalized for heart failure in the previous 12 months.
Recent data from a study by Northwell Health demonstrated that
use of the CardioMEMS HF System leads to significant improvements in quality of
life and ability to exercise in patients with chronic heart failure.
failure is the leading cause of hospitalization for Americans over age 65.
According to the American Heart
estimated direct and indirect cost of heart failure in the U.S. in 2012 was $31
billion and that number is expected to more than double by 2030.
The CardioMEMS HF System, from global medical device manufacturer Abbott, is approved by the U.S. Food and Drug Administration (FDA) for commercial use in the U.S. For more information, visit http://www.heartfailureanswers.com/.